CN1319959C - 抗发炎、治疗牛皮癣和抑制蛋白质致活酶的羟基芪、芪衍生物及其类似物 - Google Patents
抗发炎、治疗牛皮癣和抑制蛋白质致活酶的羟基芪、芪衍生物及其类似物 Download PDFInfo
- Publication number
- CN1319959C CN1319959C CNB008167559A CN00816755A CN1319959C CN 1319959 C CN1319959 C CN 1319959C CN B008167559 A CNB008167559 A CN B008167559A CN 00816755 A CN00816755 A CN 00816755A CN 1319959 C CN1319959 C CN 1319959C
- Authority
- CN
- China
- Prior art keywords
- trans
- stilbene
- carbon
- compound
- sec
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003909 protein kinase inhibitor Substances 0.000 title description 5
- 239000003795 chemical substances by application Substances 0.000 title description 3
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
- 201000004681 Psoriasis Diseases 0.000 claims abstract description 28
- 208000031737 Tissue Adhesions Diseases 0.000 claims abstract description 5
- 206010052779 Transplant rejections Diseases 0.000 claims abstract description 5
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 83
- 229910052799 carbon Inorganic materials 0.000 claims description 41
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 35
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 claims description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 235000021286 stilbenes Nutrition 0.000 claims description 24
- 239000001257 hydrogen Substances 0.000 claims description 21
- 229910052739 hydrogen Inorganic materials 0.000 claims description 21
- 125000000217 alkyl group Chemical group 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 20
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 15
- 206010061218 Inflammation Diseases 0.000 claims description 15
- 125000002252 acyl group Chemical group 0.000 claims description 15
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 230000004054 inflammatory process Effects 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 9
- 102000001253 Protein Kinase Human genes 0.000 claims description 8
- 125000004423 acyloxy group Chemical group 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 206010020718 hyperplasia Diseases 0.000 claims description 8
- 210000000440 neutrophil Anatomy 0.000 claims description 8
- 108060006633 protein kinase Proteins 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 5
- 208000034189 Sclerosis Diseases 0.000 claims description 4
- 150000001721 carbon Chemical group 0.000 claims description 4
- 206010025135 lupus erythematosus Diseases 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- 208000026935 allergic disease Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 208000037803 restenosis Diseases 0.000 claims description 3
- 206010012442 Dermatitis contact Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 208000027515 Tracheal disease Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000010247 contact dermatitis Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
- 201000003068 rheumatic fever Diseases 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 4
- 229910052794 bromium Inorganic materials 0.000 claims 4
- 239000004593 Epoxy Substances 0.000 claims 3
- 125000003700 epoxy group Chemical group 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010012434 Dermatitis allergic Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000002596 correlated effect Effects 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 45
- 108090000623 proteins and genes Proteins 0.000 abstract description 6
- 102000004169 proteins and genes Human genes 0.000 abstract description 4
- AYPZAZPOYROADP-UHFFFAOYSA-N 2-(2-phenylethenyl)phenol Chemical class OC1=CC=CC=C1C=CC1=CC=CC=C1 AYPZAZPOYROADP-UHFFFAOYSA-N 0.000 abstract description 2
- 208000027866 inflammatory disease Diseases 0.000 abstract description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 75
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 54
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 37
- 230000000694 effects Effects 0.000 description 26
- 238000000034 method Methods 0.000 description 18
- -1 hydroxyl stilbene Chemical compound 0.000 description 16
- 239000002674 ointment Substances 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 238000002425 crystallisation Methods 0.000 description 12
- 230000008025 crystallization Effects 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 108091000080 Phosphotransferase Proteins 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 102000020233 phosphotransferase Human genes 0.000 description 9
- 101001001642 Xenopus laevis Serine/threonine-protein kinase pim-3 Proteins 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 102000003916 Arrestin Human genes 0.000 description 7
- 108090000328 Arrestin Proteins 0.000 description 7
- 125000000753 cycloalkyl group Chemical group 0.000 description 7
- 235000014347 soups Nutrition 0.000 description 7
- 125000002769 thiazolinyl group Chemical group 0.000 description 7
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 6
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 208000037976 chronic inflammation Diseases 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 235000019439 ethyl acetate Nutrition 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- 229960001866 silicon dioxide Drugs 0.000 description 5
- 235000012239 silicon dioxide Nutrition 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 4
- 229910010082 LiAlH Inorganic materials 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000006020 chronic inflammation Effects 0.000 description 4
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 230000011132 hemopoiesis Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 229940043355 kinase inhibitor Drugs 0.000 description 4
- 239000002480 mineral oil Substances 0.000 description 4
- 235000010446 mineral oil Nutrition 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000012264 purified product Substances 0.000 description 4
- 230000008719 thickening Effects 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- FLVZWTAFYAPWGP-MDZDMXLPSA-N CCC1=CC=C(C=C1)/C=C/C2=CC(=CC(=C2)OC)OC Chemical compound CCC1=CC=C(C=C1)/C=C/C2=CC(=CC(=C2)OC)OC FLVZWTAFYAPWGP-MDZDMXLPSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- ULQQGOGMQRGFFR-UHFFFAOYSA-N 2-chlorobenzenecarboperoxoic acid Chemical compound OOC(=O)C1=CC=CC=C1Cl ULQQGOGMQRGFFR-UHFFFAOYSA-N 0.000 description 2
- LULAYUGMBFYYEX-UHFFFAOYSA-N 3-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 2
- NUTRHYYFCDEALP-UHFFFAOYSA-N 4-bromo-3,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=C(Br)C(O)=C1 NUTRHYYFCDEALP-UHFFFAOYSA-N 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 2
- 101000595531 Homo sapiens Serine/threonine-protein kinase pim-1 Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- PRQROPMIIGLWRP-UHFFFAOYSA-N N-formyl-methionyl-leucyl-phenylalanin Chemical compound CSCCC(NC=O)C(=O)NC(CC(C)C)C(=O)NC(C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-UHFFFAOYSA-N 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 208000038016 acute inflammation Diseases 0.000 description 2
- 230000006022 acute inflammation Effects 0.000 description 2
- 230000002682 anti-psoriatic effect Effects 0.000 description 2
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Substances OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- SLPJGDQJLTYWCI-UHFFFAOYSA-N dimethyl-(4,5,6,7-tetrabromo-1h-benzoimidazol-2-yl)-amine Chemical compound BrC1=C(Br)C(Br)=C2NC(N(C)C)=NC2=C1Br SLPJGDQJLTYWCI-UHFFFAOYSA-N 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229940095102 methyl benzoate Drugs 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 150000002924 oxiranes Chemical class 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- BDZBKCUKTQZUTL-UHFFFAOYSA-N triethyl phosphite Chemical compound CCOP(OCC)OCC BDZBKCUKTQZUTL-UHFFFAOYSA-N 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 239000003871 white petrolatum Substances 0.000 description 2
- PNVPNXKRAUBJGW-UHFFFAOYSA-N (2-chloroacetyl) 2-chloroacetate Chemical compound ClCC(=O)OC(=O)CCl PNVPNXKRAUBJGW-UHFFFAOYSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- TWYYFYNJOJGNFP-CUXYNZQBSA-N (2s,4r,5s,6s)-2-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-2-carbamoyl-4-[[(e,4s,6s)-4,6-dimethyloct-2-enoyl]oxymethyl]-5-hydroxy-1,3-dioxane-4,5,6-tricarboxylic acid Chemical compound O1[C@H](C(O)=O)[C@](C(O)=O)(O)[C@](COC(=O)/C=C/[C@@H](C)C[C@@H](C)CC)(C(O)=O)O[C@]1(C(N)=O)CCC(=C)[C@@H](OC(C)=O)[C@H](C)CC1=CC=CC=C1 TWYYFYNJOJGNFP-CUXYNZQBSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- BIYGTLDPTJMNET-CMDGGOBGSA-N (E)-3,5-Dimethoxystilbene Chemical compound COC1=CC(OC)=CC(\C=C\C=2C=CC=CC=2)=C1 BIYGTLDPTJMNET-CMDGGOBGSA-N 0.000 description 1
- GDHNBPHYVRHYCC-SNAWJCMRSA-N 1,3-dimethoxy-5-[(e)-2-(4-methoxyphenyl)ethenyl]benzene Chemical compound C1=CC(OC)=CC=C1\C=C\C1=CC(OC)=CC(OC)=C1 GDHNBPHYVRHYCC-SNAWJCMRSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- QSSXJPIWXQTSIX-UHFFFAOYSA-N 1-bromo-2-methylbenzene Chemical compound CC1=CC=CC=C1Br QSSXJPIWXQTSIX-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- AYPZAZPOYROADP-ZHACJKMWSA-N 2-[(e)-2-phenylethenyl]phenol Chemical compound OC1=CC=CC=C1\C=C\C1=CC=CC=C1 AYPZAZPOYROADP-ZHACJKMWSA-N 0.000 description 1
- MSSQOQPKGAMUSY-LEAFIULHSA-N 2-[1-[2-[(4r,6s)-8-chloro-6-(2,3-dimethoxyphenyl)-4,6-dihydropyrrolo[1,2-a][4,1]benzoxazepin-4-yl]acetyl]piperidin-4-yl]acetic acid Chemical compound COC1=CC=CC([C@@H]2C3=CC(Cl)=CC=C3N3C=CC=C3[C@@H](CC(=O)N3CCC(CC(O)=O)CC3)O2)=C1OC MSSQOQPKGAMUSY-LEAFIULHSA-N 0.000 description 1
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
- FNRMMDCDHWCQTH-UHFFFAOYSA-N 2-chloropyridine;3-chloropyridine;4-chloropyridine Chemical compound ClC1=CC=NC=C1.ClC1=CC=CN=C1.ClC1=CC=CC=N1 FNRMMDCDHWCQTH-UHFFFAOYSA-N 0.000 description 1
- ZJSCAZNZJKSFGX-CMDGGOBGSA-N 2-ethyl-5-[(e)-2-phenylethenyl]benzene-1,3-diol Chemical compound C1=C(O)C(CC)=C(O)C=C1\C=C\C1=CC=CC=C1 ZJSCAZNZJKSFGX-CMDGGOBGSA-N 0.000 description 1
- CXHUAGXEAIRSGS-QZQOTICOSA-N 5-[(e)-2-phenylethenyl]-2-tetradecylbenzene-1,3-diol Chemical compound C1=C(O)C(CCCCCCCCCCCCCC)=C(O)C=C1\C=C\C1=CC=CC=C1 CXHUAGXEAIRSGS-QZQOTICOSA-N 0.000 description 1
- 101800000263 Acidic protein Proteins 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 229910015845 BBr3 Inorganic materials 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- UAEMLKAEMJIUKO-ZHACJKMWSA-N C1(C(C=CC=C1)=O)\C=C\C1=CC=CC=C1 Chemical compound C1(C(C=CC=C1)=O)\C=C\C1=CC=CC=C1 UAEMLKAEMJIUKO-ZHACJKMWSA-N 0.000 description 1
- VBUXXBBBGVGBGQ-QURGRASLSA-N CCCCCCCCCCCCCCC1=CC=C(C=C1)/C=C/C2=CC(=CC(=C2)OC)OC Chemical compound CCCCCCCCCCCCCCC1=CC=C(C=C1)/C=C/C2=CC(=CC(=C2)OC)OC VBUXXBBBGVGBGQ-QURGRASLSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000052052 Casein Kinase II Human genes 0.000 description 1
- 108010010919 Casein Kinase II Proteins 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101100352234 Homo sapiens PIM1 gene Proteins 0.000 description 1
- 238000006052 Horner reaction Methods 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- 102000015335 Ku Autoantigen Human genes 0.000 description 1
- 108010025026 Ku Autoantigen Proteins 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 101100352235 Mus musculus Pim1 gene Proteins 0.000 description 1
- 208000000592 Nasal Polyps Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000015537 Protein Kinase C-alpha Human genes 0.000 description 1
- 108010050276 Protein Kinase C-alpha Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000669298 Pseudaulacaspis pentagona Species 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100036077 Serine/threonine-protein kinase pim-1 Human genes 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001399 anti-metabolic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 229960003328 benzoyl peroxide Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000013000 chemical inhibitor Substances 0.000 description 1
- 239000012627 chemopreventive agent Substances 0.000 description 1
- 229940124443 chemopreventive agent Drugs 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- BIYGTLDPTJMNET-UHFFFAOYSA-N cis-pinosylvin dimethyl ether Natural products COC1=CC(OC)=CC(C=CC=2C=CC=CC=2)=C1 BIYGTLDPTJMNET-UHFFFAOYSA-N 0.000 description 1
- 239000011285 coke tar Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940125876 compound 15a Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 230000036566 epidermal hyperplasia Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- MEVGXDKUAKIUGO-UHFFFAOYSA-N ethyl 3-phenylpropyl hydrogen phosphate Chemical compound CCOP(O)(=O)OCCCC1=CC=CC=C1 MEVGXDKUAKIUGO-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000005861 gene abnormality Effects 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 229940059904 light mineral oil Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 208000016366 nasal cavity polyp Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 206010035653 pneumoconiosis Diseases 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- TZSZZENYCISATO-WIOPSUGQSA-N rodatristat Chemical compound CCOC(=O)[C@@H]1CC2(CN1)CCN(CC2)c1cc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)nc(N)n1 TZSZZENYCISATO-WIOPSUGQSA-N 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229940126672 traditional medicines Drugs 0.000 description 1
- YCVPRTHEGLPYPB-VOTSOKGWSA-N trans-pinosylvin Chemical compound OC1=CC(O)=CC(\C=C\C=2C=CC=CC=2)=C1 YCVPRTHEGLPYPB-VOTSOKGWSA-N 0.000 description 1
- 235000018991 trans-resveratrol Nutrition 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- WQEVDHBJGNOKKO-UHFFFAOYSA-K vanadic acid Chemical compound O[V](O)(O)=O WQEVDHBJGNOKKO-UHFFFAOYSA-K 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
- C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
- C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/14—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by free hydroxyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/16—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by esterified hydroxyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Description
成分 | 量 |
活性成分(本发明化合物) | 0.05-20.0mg |
乙醇 | 100μl |
矿物油,USP | 50.0mg |
白色矿脂,USP | 制成1.0g |
成分 | 量 |
活性成分(本发明化合物) | 0.05-20.0mg |
乙醇 | 100μl |
微粒化了的单硬脂酸铝 | 50.0mg |
肉豆蔻酸异丙酯 | 制成1.0g |
成分 | 量 |
活性成分(本发明化合物) | 0.05-20.0mg |
乙醇 | 100μl |
聚乙烯及共聚物(A-C8) | 100.0mg |
轻矿物油 | 制成1.0g |
成分 | 量 |
活性成分(本发明化合物) | 0.05-20.0mg |
乙醇 | 100μl |
基于Glaxal的乳剂 | 制成1.0g |
致活酶 | IC50(mM) | ||
EP | CST | STA | |
Lck | 0.10 | 0.27 | 0.54 |
Ck2 | 0.31 | 0.13 | Nd* |
DNA-Pk | 0.16 | 0.55 | Nd |
Pim-1 | 0.16 | 0.18 | Nd |
Claims (6)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16875899P | 1999-12-06 | 1999-12-06 | |
US60/168,758 | 1999-12-06 | ||
US17330099P | 1999-12-28 | 1999-12-28 | |
US60/173,300 | 1999-12-28 | ||
PCT/CA2000/001433 WO2001042231A2 (en) | 1999-12-06 | 2000-12-06 | Polyhydroxystilbenes and stilbene oxides as antisoriatic agents and protein kinase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1407978A CN1407978A (zh) | 2003-04-02 |
CN1319959C true CN1319959C (zh) | 2007-06-06 |
Family
ID=26864425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB008167559A Expired - Lifetime CN1319959C (zh) | 1999-12-06 | 2000-12-06 | 抗发炎、治疗牛皮癣和抑制蛋白质致活酶的羟基芪、芪衍生物及其类似物 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20030171429A1 (zh) |
EP (1) | EP1248774B1 (zh) |
JP (1) | JP4880847B2 (zh) |
KR (1) | KR100805907B1 (zh) |
CN (1) | CN1319959C (zh) |
AT (1) | ATE444960T1 (zh) |
CA (1) | CA2393297C (zh) |
DE (1) | DE60043120D1 (zh) |
ES (1) | ES2334635T3 (zh) |
HK (1) | HK1051691A1 (zh) |
WO (1) | WO2001042231A2 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101564537B (zh) * | 2009-06-08 | 2011-05-25 | 河北科技大学 | 3,5-二羟基-4-异丙基二苯乙烯-溴乙酸乙酯-聚乙二醇复合物及其合成方法 |
CN107666902A (zh) * | 2015-05-21 | 2018-02-06 | 葛兰素史密斯克莱知识产权发展有限公司 | 局部药物组合物 |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7321050B2 (en) | 1999-12-06 | 2008-01-22 | Welichem Biotech Inc. | Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues |
US6552085B2 (en) | 2000-08-16 | 2003-04-22 | Insmed Incorporated | Compositions containing hypoglycemically active stilbenoids |
US6410596B1 (en) * | 2000-08-16 | 2002-06-25 | Insmed Incorporated | Compositions containing hypoglycemically active stillbenoids |
JP4230770B2 (ja) * | 2001-01-18 | 2009-02-25 | ウェリケム バイオテック インコーポレーテッド | 免疫性疾患を治療するための新規な1,2−ジフェニルエテン誘導体 |
AU2002319677B8 (en) * | 2001-07-23 | 2009-04-30 | Atwater Management Llc | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods |
US7384920B2 (en) | 2001-07-26 | 2008-06-10 | Institute Of Radiation Medicine, Academy Of Military Medical Sciences, Pla | Use of stilbene compounds in the manufacture of medicament for the prevention and treatment of diabetes or retrovirus-associated diseases |
FR2830860A1 (fr) * | 2001-10-12 | 2003-04-18 | Univ Pasteur | Procede de synthese du (z)-3, 5, 4'-trimethoxystilbene, compose obtenu et utilisations dudit compose, notamment comme medicament, en particulier comme anticancereux |
CN101810600B (zh) * | 2001-11-02 | 2012-11-21 | 加州大学校务委员会 | 用于预防和治疗炎性疾病,自体免疫性疾病,和移植排斥的组成物及方法 |
JP4483581B2 (ja) * | 2002-08-06 | 2010-06-16 | 東レ株式会社 | 腎疾患治療又は予防剤及び腎疾患の診断方法 |
US20050080021A1 (en) * | 2002-08-15 | 2005-04-14 | Joseph Tucker | Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders |
US20050080024A1 (en) * | 2002-08-15 | 2005-04-14 | Joseph Tucker | Nitric oxide donating derivatives for the treatment of cardiovascular disorders |
AU2003272548A1 (en) * | 2002-09-16 | 2004-04-30 | Plexxikon, Inc. | Crystal structure of pim-1 kinase |
KR20050062581A (ko) * | 2002-10-01 | 2005-06-23 | 웰리켐 바이오 테크 인크. | 신규의 생물활성 디페닐 에텐 화합물 및 그의 치료학적용도 |
GB2411353A (en) * | 2004-02-25 | 2005-08-31 | Univ Hertfordshire | Resveratrol Analogues |
WO2006045010A2 (en) * | 2004-10-20 | 2006-04-27 | Resverlogix Corp. | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
EP2314295B1 (en) * | 2005-07-29 | 2015-01-28 | Resverlogix, Inc | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
WO2007084857A2 (en) * | 2006-01-13 | 2007-07-26 | President And Fellows Of Harvard College | Methods and compositions for treating cell proliferative disorders |
US8980954B2 (en) * | 2006-04-25 | 2015-03-17 | Stc.Unm | Substituted cis- and trans-stilbenes as therapeutic agents |
PL2118074T3 (pl) | 2007-02-01 | 2014-06-30 | Resverlogix Corp | Związki chemiczne do celów profilaktyki i leczenia chorób układu sercowo-naczyniowego |
WO2009008991A2 (en) * | 2007-07-06 | 2009-01-15 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health | Dna-pkcs modulates energy regulation and brain function |
FI125590B (en) | 2008-04-10 | 2015-12-15 | Neste Oyj | A process for the preparation of a composition for the preparation of pinosylvine and its compounds, a composition for the preparation of stilbene compounds, a process for the recovery of stilbene compounds, and fatty acid and resin acid esters of pinosylvine and its monomethyl ether |
CN101970416B (zh) | 2008-06-26 | 2014-05-28 | 雷斯韦洛吉克斯公司 | 制备喹唑啉酮衍生物的方法 |
WO2010046926A2 (en) * | 2008-10-17 | 2010-04-29 | Aptuit Laurus Pvt Ltd | Novel stilbene analogs |
NZ594332A (en) | 2009-01-08 | 2013-09-27 | Resverlogix Corp | Compounds for the prevention and treatment of cardiovascular disease |
US9050284B2 (en) * | 2009-02-09 | 2015-06-09 | Sami Labs Limited | Orally bioavailable stilbenoids—compositions and therapeutic applications thereof |
US20100204340A1 (en) * | 2009-02-09 | 2010-08-12 | Muhammed Majeed | Orally bioavailable stilbenoids- compositions and therapeutic applications thereof |
AU2010224523B2 (en) | 2009-03-18 | 2014-05-08 | Resverlogix Corp. | Novel anti-inflammatory agents |
CN101531571B (zh) * | 2009-04-17 | 2013-03-20 | 河北科技大学 | 六次甲基四胺氧化合成二苯乙烯类化合物的方法 |
LT2421533T (lt) | 2009-04-22 | 2018-12-27 | Resverlogix Corp. | Nauji priešuždegiminiai agentai |
CN101543477B (zh) * | 2009-05-06 | 2011-01-19 | 河北科技大学 | 壳聚糖包覆3,5-二羟基-4-异丙基二苯乙烯的缓释微球及其制备方法 |
CN101564538B (zh) * | 2009-06-08 | 2011-12-07 | 河北科技大学 | 3,5-二羟基-4-异丙基二苯乙烯-丁二酸酐-聚乙二醇复合物及其合成方法 |
US9610251B2 (en) | 2011-11-01 | 2017-04-04 | Resverlogix Corp. | Pharmaceutical compositions for substituted quinazolinones |
CN102579322B (zh) * | 2012-03-29 | 2013-10-23 | 河北科技大学 | 一种外用水凝胶剂及其制备方法与它的用途 |
CN102657602B (zh) * | 2012-05-22 | 2013-08-07 | 河北科技大学 | 3,5-二羟基-4-异丙基二苯乙烯壳聚糖凝胶剂及其制备方法 |
WO2014080290A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
WO2014080291A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
CN105073744B (zh) | 2012-12-21 | 2019-11-08 | 齐尼思表观遗传学有限公司 | 作为溴结构域抑制剂的新型杂环化合物 |
CA2970739C (en) | 2014-12-12 | 2023-10-03 | Glaxosmithkline Intellectual Property Development Limited | Use of 3,5-dihydroxy-4-isopropyl-trans-stilbene, for treating skin conditions |
US10111885B2 (en) | 2015-03-13 | 2018-10-30 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
US11617724B2 (en) | 2015-05-21 | 2023-04-04 | Dermavant Sciences GmbH | Topical pharmaceutical compositions |
CN106467502A (zh) * | 2015-08-21 | 2017-03-01 | 南京理工大学 | 2,3-二芳基环氧乙烷化合物及其制备方法 |
US9725406B1 (en) * | 2016-10-13 | 2017-08-08 | Resolvex Pharmaceuticals Inc. | Substituted hydroxystilbenes and their therapeutic applications |
BR112020009158A2 (pt) * | 2017-11-10 | 2020-10-27 | Dermavant Sciences GmbH | processo para o preparo de um composto, composto e composição farmacêutica |
KR102233566B1 (ko) * | 2018-05-04 | 2021-03-30 | 서울대학교산학협력단 | 스틸벤 유도체를 포함하는 만성 폐질환의 예방 또는 치료용 조성물 |
US11497718B2 (en) | 2018-11-13 | 2022-11-15 | Dermavant Sciences GmbH | Use of tapinarof for the treatment of atopic dermatitis |
KR20220041125A (ko) * | 2019-07-24 | 2022-03-31 | 솔-겔 테크놀로지스 리미티드 | 국부 타피나로프-egfr 억제제 조성물을 이용한 피부 장애의 치료 |
EP4153551A1 (en) | 2020-05-19 | 2023-03-29 | Teva Pharmaceuticals International GmbH | Solid state forms of tapinarof |
CN113735693B (zh) * | 2021-10-20 | 2023-07-14 | 河北维达康生物科技有限公司 | 一种白藜芦醇三甲醚的合成方法 |
CN116350609A (zh) * | 2021-12-28 | 2023-06-30 | 上海泽德曼医药科技有限公司 | 用于抑制血管内皮生长的化合物及其用途 |
WO2023217049A1 (zh) * | 2022-05-07 | 2023-11-16 | 南京济群医药科技股份有限公司 | 作为AhR激动剂的二苯乙烯衍生物及其用途 |
CN115557963A (zh) * | 2022-06-13 | 2023-01-03 | 大连大学 | 一类具有抗炎活性的聚酮类化合物及其制备方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0170105A2 (en) * | 1984-07-07 | 1986-02-05 | Koichi Prof. Dr. Shudo | Benzoic acid derivatives |
JPH0753359A (ja) * | 1993-06-11 | 1995-02-28 | Kao Corp | リポキシゲナーゼ阻害剤 |
WO1999040056A1 (en) * | 1998-02-06 | 1999-08-12 | De Montfort University | Hydroxylation activated prodrugs |
WO1999059561A2 (en) * | 1998-05-18 | 1999-11-25 | Hensley, Kenneth, L. | Resveratrol inhibition of myeloperoxidase |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5111748A (en) * | 1974-07-16 | 1976-01-30 | Taisho Pharmaceutical Co Ltd | Suchirubenjudotaino seizoho |
JPS58159410A (ja) * | 1982-03-18 | 1983-09-21 | Mitsubishi Chem Ind Ltd | 抗炎症剤 |
JPS6122046A (ja) * | 1984-07-07 | 1986-01-30 | Koichi Shiyudo | スチルベン誘導体 |
LU85558A1 (fr) * | 1984-09-28 | 1986-04-03 | Oreal | Nouveaux derives naphtaleniques a action retinoique,leurs procedes de preparation et compositions medicamenteuse et cosmetique les contenant |
US4788304A (en) * | 1987-12-07 | 1988-11-29 | American Home Products Corporation | Phospholipase A2 inhibitors |
US4933365A (en) * | 1989-01-25 | 1990-06-12 | American Home Products Corporation | Phospholipase A2 inhibitors |
GB9106177D0 (en) * | 1991-03-22 | 1991-05-08 | Aston Molecules Ltd | Substituted diphenylethylenes and analogues or derivatives thereof |
FR2676052B1 (fr) * | 1991-05-02 | 1994-04-29 | Cird Galderma | Nouveaux composes polycycliques aromatiques et leur utilisation en medecine humaine ou veterinaire et en cosmetique. |
GB9204945D0 (en) * | 1992-03-06 | 1992-04-22 | Erba Carlo Spa | 3-aryl-glycidic ester derivatives and process for their preparation |
US5430062A (en) * | 1992-05-21 | 1995-07-04 | Research Corporation Technologies, Inc. | Stilbene derivatives as anticancer agents |
US5556996A (en) * | 1994-12-29 | 1996-09-17 | Allergan | Oxiranyls disubstituted with a phenyl group and a substituted chromanyl or tetrahydroquinolinyl group having retinoid like activity |
JPH08337523A (ja) * | 1995-06-14 | 1996-12-24 | Taiho Yakuhin Kogyo Kk | 血管新生阻害剤 |
US6008260A (en) * | 1998-01-09 | 1999-12-28 | Pharmascience | Cancer chemopreventative composition and method |
FR2785284B1 (fr) * | 1998-11-02 | 2000-12-01 | Galderma Res & Dev | Analogues de la vitamine d |
-
2000
- 2000-12-06 ES ES00984681T patent/ES2334635T3/es not_active Expired - Lifetime
- 2000-12-06 JP JP2001543531A patent/JP4880847B2/ja not_active Expired - Lifetime
- 2000-12-06 AT AT00984681T patent/ATE444960T1/de not_active IP Right Cessation
- 2000-12-06 KR KR1020027007240A patent/KR100805907B1/ko active IP Right Grant
- 2000-12-06 DE DE60043120T patent/DE60043120D1/de not_active Expired - Lifetime
- 2000-12-06 US US10/148,863 patent/US20030171429A1/en not_active Abandoned
- 2000-12-06 WO PCT/CA2000/001433 patent/WO2001042231A2/en active IP Right Grant
- 2000-12-06 CA CA2393297A patent/CA2393297C/en not_active Expired - Lifetime
- 2000-12-06 EP EP00984681A patent/EP1248774B1/en not_active Expired - Lifetime
- 2000-12-06 CN CNB008167559A patent/CN1319959C/zh not_active Expired - Lifetime
-
2003
- 2003-06-06 HK HK03104013A patent/HK1051691A1/xx not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0170105A2 (en) * | 1984-07-07 | 1986-02-05 | Koichi Prof. Dr. Shudo | Benzoic acid derivatives |
JPH0753359A (ja) * | 1993-06-11 | 1995-02-28 | Kao Corp | リポキシゲナーゼ阻害剤 |
WO1999040056A1 (en) * | 1998-02-06 | 1999-08-12 | De Montfort University | Hydroxylation activated prodrugs |
WO1999059561A2 (en) * | 1998-05-18 | 1999-11-25 | Hensley, Kenneth, L. | Resveratrol inhibition of myeloperoxidase |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101564537B (zh) * | 2009-06-08 | 2011-05-25 | 河北科技大学 | 3,5-二羟基-4-异丙基二苯乙烯-溴乙酸乙酯-聚乙二醇复合物及其合成方法 |
CN107666902A (zh) * | 2015-05-21 | 2018-02-06 | 葛兰素史密斯克莱知识产权发展有限公司 | 局部药物组合物 |
CN107666902B (zh) * | 2015-05-21 | 2021-09-21 | 德玛万科学有限责任公司 | 局部药物组合物 |
Also Published As
Publication number | Publication date |
---|---|
ES2334635T3 (es) | 2010-03-15 |
EP1248774A2 (en) | 2002-10-16 |
AU2133001A (en) | 2001-06-18 |
ATE444960T1 (de) | 2009-10-15 |
JP4880847B2 (ja) | 2012-02-22 |
JP2003516400A (ja) | 2003-05-13 |
HK1051691A1 (en) | 2003-08-15 |
AU780700B2 (en) | 2005-04-14 |
KR100805907B1 (ko) | 2008-02-21 |
CA2393297C (en) | 2010-10-05 |
US20030171429A1 (en) | 2003-09-11 |
CA2393297A1 (en) | 2001-06-14 |
EP1248774B1 (en) | 2009-10-07 |
WO2001042231A3 (en) | 2001-11-01 |
DE60043120D1 (de) | 2009-11-19 |
CN1407978A (zh) | 2003-04-02 |
KR20020070310A (ko) | 2002-09-05 |
WO2001042231A2 (en) | 2001-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1319959C (zh) | 抗发炎、治疗牛皮癣和抑制蛋白质致活酶的羟基芪、芪衍生物及其类似物 | |
CN1185223C (zh) | 新颖化合物,其合成方法及治疗用途 | |
CN1281606C (zh) | 含氮杂环化合物 | |
CN1031705C (zh) | 24-加碳-维生素-d-衍生物的制备方法 | |
WO2006100453A1 (en) | Glycopyrronium salts and their therapeutic use | |
CN1274285A (zh) | α-酮酰胺多元催化蛋白酶抑制剂 | |
CN1305465A (zh) | 芳基链烷酰基哒嗪化合物 | |
CA2387591A1 (fr) | Utilisation de derives d'indirubine pour la fabrication de medicaments | |
CN1688535A (zh) | 新型生物活性的二苯乙烯化合物及其医疗用途 | |
CN1729007A (zh) | 用于预防和治疗炎性疾病,自体免疫性疾病,和移植排斥的组成物及方法 | |
CN101029046A (zh) | 取代的异穿心莲内酯衍生物、制备方法及其药物组合物 | |
CN1455766A (zh) | 治疗免疫疾病的新的1,2-二苯基乙烯衍生物 | |
CN1149046A (zh) | 新的取代2,2-二甲基-ω-苯氧链烷酸及酯,其制备方法及含有它们的药物组合物 | |
CN114555569A (zh) | Nlrp3调节剂 | |
CN1047869A (zh) | 表鬼臼毒吡喃葡糖甙的酰化衍生物 | |
CN1126737C (zh) | 新型吡咯化合物和其制备方法及含其的药物组合物 | |
CN1065241C (zh) | 在7位上用氟取代的2,3-二脱氢唾液酸及其合成中间体 | |
CN1555351A (zh) | 制备不饱和脂族羟基酸及其酯的方法、在药物和/或化妆品组合物中的应用 | |
CN1078720A (zh) | 丁二烯衍生物及其制备方法 | |
CN101028260A (zh) | 取代的异穿心莲内酯衍生物的用途 | |
CN1172930C (zh) | 抑制pdeiv之吡啶衍生物类 | |
CN1152011C (zh) | 维生素d类似物及其药物用途 | |
CN100349884C (zh) | 3-苯基呋喃-2-酮衍生物作为环加氧酶的抑制剂 | |
CN1104209A (zh) | 2,4-二氨基-3-羟基羧酸衍生物 | |
CA3137190A1 (en) | Compositions and methods for inhibiting blood cancer cell growth |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: TIANJI PHARMACEUTICAL( SHENZHEN ) CO., LTD. Free format text: FORMER OWNER: CHEN GENGHUI Effective date: 20060310 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20060310 Address after: 518057, B, building 716, building R3, hi tech Industrial Village, Shennan Avenue, Guangdong, Shenzhen Applicant after: Tianji Pharmaceutical (Shenzhen) Co.,Ltd. Address before: British Columbia Canada Burnaby Applicant before: Chen Genghui |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BEIJING WENFENG TIANJI PHARMACEUTICAL TECHNOLOGY C Free format text: FORMER OWNER: SHENZHEN CELESTIAL PHARMACEUTICALS CO., LTD. Effective date: 20110527 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee |
Owner name: SHENZHEN CELESTIAL PHARMACEUTICALS CO., LTD. Free format text: FORMER NAME: CELESTIAL PHARMACEUTICALS SHENZHEN |
|
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 518057 ROOM 716, TOWER B, BUILDING R3, HIGH-TECH. INDUSTRIAL VILLAGE, SHENNAN AVENUE, SHENZHEN CITY, GUANGDONG PROVINCE TO: 102206 B254, INNOVATION BUILDING, NO. 29, SHENGMINGYUAN ROAD, CHANGPING DISTRICT, BEIJING |
|
CP01 | Change in the name or title of a patent holder |
Address after: 518057, B, building 716, building R3, hi tech Industrial Village, Shennan Avenue, Guangdong, Shenzhen Patentee after: Shenzhen 100041 Pharmaceutical Co.,Ltd. Address before: 518057, B, building 716, building R3, hi tech Industrial Village, Shennan Avenue, Guangdong, Shenzhen Patentee before: Tianji Pharmaceutical (Shenzhen) Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20110527 Address after: 102206 innovation building B254, 29 life road, Beijing, Changping District Patentee after: BEIJING WEN FENG TIANJI PHARMA Co.,Ltd. Address before: 518057, B, building 716, building R3, hi tech Industrial Village, Shennan Avenue, Guangdong, Shenzhen Patentee before: Shenzhen 100041 Pharmaceutical Co.,Ltd. |
|
CX01 | Expiry of patent term |
Granted publication date: 20070606 |
|
CX01 | Expiry of patent term |